Methotrexate plus or minus cetuximab as first‐line treatment in a recurrent or metastatic (R/M) squamous cell carcinoma population of the head and neck (SCCHN) …

JC Ham, E van Meerten, WE Fiets, LV Beerepoot… - Head & …, 2020 - Wiley Online Library
Background Methotrexate in recurrent or metastatic (R/M) squamous cell carcinoma of the
head and neck (SCCHN) has limited progression‐free survival (PFS) benefit. We …
被引用次数：18 相关文章
[PDF] universiteitleiden.nl

[PDF][PDF] Methotrexate plus or minus cetuximab as first-line treatment in a recurrent or metastatic (R/M) squamous cell carcinoma population of the head and neck …

JCH MD, E van Meerten PhD… - 2020 - scholarlypublications …
Background: Methotrexate in recurrent or metastatic (R/M) squamous cell carcinoma of the
head and neck (SCCHN) has limited progression-free survival (PFS) benefit. We …

Methotrexate plus or minus cetuximab as first-line treatment in a recurrent or metastatic (R/M) squamous cell carcinoma population of the head and neck (SCCHN) …

JC Ham, E van Meerten, WE Fiets, LV Beerepoot… - Head & …, 2020 - europepmc.org
Background Methotrexate in recurrent or metastatic (R/M) squamous cell carcinoma of the
head and neck (SCCHN) has limited progression-free survival (PFS) benefit. We …
[PDF] archive.org

[PDF][PDF] Methotrexate plus or minus cetuximab as first-line treatment in a recurrent or metastatic (R/M) squamous cell carcinoma population of the head and neck …

E van Meerten PhD, WTA van der Graaf PhD… - 2020 - scholar.archive.org
Background: Methotrexate in recurrent or metastatic (R/M) squamous cell carcinoma of the
head and neck (SCCHN) has limited progression-free survival (PFS) benefit. We …
[HTML] nih.gov

[HTML][HTML] Methotrexate plus or minus cetuximab as first‐line treatment in a recurrent or metastatic (R/M) squamous cell carcinoma population of the head and neck …

JC Ham, E van Meerten, WE Fiets, LV Beerepoot… - Head & …, 2020 - ncbi.nlm.nih.gov
Background Methotrexate in recurrent or metastatic (R/M) squamous cell carcinoma of the
head and neck (SCCHN) has limited progression‐free survival (PFS) benefit. We …

Methotrexate plus or minus cetuximab as first‐line treatment in a recurrent or metastatic (R/M) squamous cell carcinoma population of the head and neck (SCCHN) …

JC Ham, E Meerten, WE Fiets, LV Beerepoot… - Head & …, 2020 - search.ebscohost.com
Background: Methotrexate in recurrent or metastatic (R/M) squamous cell carcinoma of the
head and neck (SCCHN) has limited progression‐free survival (PFS) benefit. We …

Methotrexate plus or minus cetuximab as first-line treatment in a recurrent or metastatic (R/M) squamous cell carcinoma population of the head and neck (SCCHN) …

JC Ham, E van Meerten, WE Fiets… - Head & …, 2020 - pubmed.ncbi.nlm.nih.gov
Background Methotrexate in recurrent or metastatic (R/M) squamous cell carcinoma of the
head and neck (SCCHN) has limited progression-free survival (PFS) benefit. We …
[PDF] academia.edu

[PDF][PDF] Methotrexate plus or minus cetuximab as first-line treatment in a recurrent or metastatic (R/M) squamous cell carcinoma population of the head and neck …

E van Meerten PhD, WTA van der Graaf PhD… - 2020 - academia.edu
Background: Methotrexate in recurrent or metastatic (R/M) squamous cell carcinoma of the
head and neck (SCCHN) has limited progression-free survival (PFS) benefit. We …
[PDF] ru.nl

[PDF][PDF] Methotrexate plus or minus cetuximab as first-line treatment in a recurrent or metastatic (R/M) squamous cell carcinoma population of the head and neck …

JC Ham, E Meerten, WE Fiets, LV Beerepoot… - 2020 - repository.ubn.ru.nl
BACKGROUND: Methotrexate in recurrent or metastatic (R/M) squamous cell carcinoma of
the head and neck (SCCHN) has limited progression-free survival (PFS) benefit. We …

Methotrexate plus or minus cetuximab as first-line treatment in a recurrent or metastatic (R/M) squamous cell carcinoma population of the head and neck (SCCHN) …

JC Ham, E van Meerten, WE Fiets, LV Beerepoot… - Head & …, 2020 - europepmc.org
Background Methotrexate in recurrent or metastatic (R/M) squamous cell carcinoma of the
head and neck (SCCHN) has limited progression-free survival (PFS) benefit. We …